Install
Korea's ENCell partners with Andelyn Biosciences to expand global reach of gene therapy manufacturing BioSpectrum Asia BioSpectrum is an integrated B2B media platform for the healthcare and bioscience industry in the Asia Pacific region.
- 166articles · 30d
- 15+ hour agolatest article
- Aug 18, 2026earliest in window
- 92%with images
- 260avg words
- Medical 109
- Health & Wellness 98
- Health 63
- Business & Industrial 57
- Science & Technology 51
- Economy, Business & Finance 50
- Science & Nature 31
- Finance & Business 22
- cf
- stock screener tool
- highest dollar trading volume
- danaher corporation designs
- cell culture media development services
- cell culture media
- lab-scale protein purification
- aseptic fill finish
- full manufacturing suites
- healthcare filtration solutions
- vertex pharmaceuticals incorporated
- treating cystic fibrosis
- clinical-stage biotechnology company
- lab filtration
- cell line
- companies
- medical news
- stocks
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
New partnership to strengthen CAR-T cell therapy manufacturing capabilities in Japan
16+ hour, 9+ min ago (258+ words) BioSpectrum Asia New partnership to strengthen CAR-T cell therapy manufacturing capabilities in Japan September 13, 2026 | Sunday | News Teijin, Teijin Regenet and Shinshu University Hospital to contribute to the advancement of cell and gene therapies in Japan Teijin Limited, Teijin Regenet Co.,…...
Singapore strengthens clinical trials capacity in collaboration with WHO
6+ day, 2+ hour ago (150+ words) September 8, 2026 | Tuesday | News Based at the Saw Swee Hock School of Public Health, National University of Singapore, ADVANCE-ID is Singapore’s 13th World Health Organisation (WHO) collaborating centre and joins a global network of institutions designated to support WHO's mandate. ADVANCE-ID will…...
DIPG Alliance to raise S$5 M over five years to establish Singapore's first enduring paediatric brain tumour research fund
1+ week, 4+ day ago (295+ words) biospectrumasia.com DIPG Alliance to raise S$5 M over five years to establish Singapore's first enduring paediatric brain tumour research fund September 2, 2026 | Wednesday | News Improving access to emerging therapies and clinical trials DIPG Alliance, Singapore's first charitable foundation dedicated to…...
Singapore expands subsidised access to Roche’s Columvi for relapsed or refractory DLBCL
1+ week, 5+ day ago (247+ words) September 1, 2026 | Tuesday | News Singapore is expanding subsidised access to Roche’s Columvi, or glofitamab, for eligible patients with relapsed or refractory diffuse large B-cell lymphoma. From 1 September 2026, Columvi will be included on the Ministry of Health’s Cancer Drug List and Medication…...
Formosa Pharma files European trial application for Kadcyla biosimilar TSY-110
2+ week, 3+ hour ago (229+ words) August 31, 2026 | Monday | News TSY-110 is being co-developed by Formosa Pharmaceuticals and EirGenix as a biosimilar to Roche’s Kadcyla. The reference therapy is used in HER2-positive metastatic and early-stage breast cancer. The planned pivotal study has been designed following regulatory guidance…...
Australia builds lung cancer research truck to transport early detection technology
2+ week, 5+ day ago (174+ words) August 25, 2026 | Tuesday | News A mobile clinic has been launched as part of an initiative of The University of Queensland (UQ) and the Australian Cancer Research Foundation (ACRF) that aims to trial state-of-the-art technology such as low-dose CT scanning and AI-enabled…...
Leads Biolabs’ opamtistomig NDA accepted in China for neuroendocrine carcinoma
2+ week, 6+ day ago (234+ words) August 24, 2026 | Monday | News Nanjing Leads Biolabs has announced that China’s Center for Drug Evaluation has accepted the New Drug Application for opamtistomig, or LBL-024, for previously treated advanced extrapulmonary neuroendocrine carcinoma. Opamtistomig is a proprietary bispecific antibody targeting PD-L1 and…...
Akeso receives China clinical trial clearance for B7-H3 ADC AK157D1
2+ week, 6+ day ago (197+ words) August 24, 2026 | Monday | News Akeso has received clinical trial clearance from China’s Center for Drug Evaluation for AK157D1, a next-generation antibody-drug conjugate targeting B7-H3. The clearance allows the company to initiate a Phase I clinical trial in patients with advanced malignant solid tumours....
CStone secures China IND approval for EGFR/HER3 bispecific ADC CS5007
2+ week, 6+ day ago (179+ words) August 24, 2026 | Monday | News The Investigational New Drug application was cleared through China’s review pathway for innovative drug clinical trials in 23 working days. The approval allows CStone to include mainland China in its ongoing global Phase I programme of CS5007. Clinical development…...
US-Japan collaboration for liquid biopsy screening in lung cancer
3+ week, 2+ day ago (134+ words) BioSpectrum Asia US-Japan collaboration for liquid biopsy screening in lung cancer August 21, 2026 | Friday | News oncoReveal® Essential+ validated at LSI Medience for cfDNA/cfRNA screening in the LC-SCRUM-Asia project, with testing planned to begin in August 2026 US-based Pillar Biosciences, Inc., LC-SCRUM-Asia…...